Market Movement Analysis: TwistBioscience surges on September 17 due to Eli Lilly partnership, AI drug development, and DNA synthesis

1. On September 16, the company reached an agreement with Lilly TuneLab, a subsidiary of Eli Lilly, to provide antibody characterization data services and to generate high-quality experimental data through preferential plans, supporting TuneLab's AI/ML drug discovery model and AbLab antibody developability prediction model.
2. On September 15, company management stated that AI-driven drug discovery and diagnostics are the main growth drivers, with the aim to achieve profitability in the fourth quarter and a plan to double revenue by 2031.
3. As of June 30, the company's quarterly revenue grew 23% year-on-year to $118.4 million; revenue from DNA synthesis and protein solutions increased by 39%, NGS application revenue grew by 12%, and gene shipment volume rose by 56% year-on-year to approximately 369,000 units.

(Disclaimer: This content is generated by AI technology based on public information and is for reference only. It does not constitute investment advice.)